Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR4195688

—

10ba162b-7f2c-5b50-8b4f-7a50318f85d4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.480
  • PROTEIN_SECRETION+0.470
  • MTORC1_SIGNALING+0.370
  • E2F_TARGETS+0.350
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
  • ANDROGEN_RESPONSE+0.320
  • ANGIOGENESIS+0.310
  • G2M_CHECKPOINT+0.310
  • COAGULATION+0.290
  • HYPOXIA+0.280

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.380
  • WNT_BETA_CATENIN_SIGNALING-0.270
  • ESTROGEN_RESPONSE_LATE-0.250
  • P53_PATHWAY-0.250
  • IL6_JAK_STAT3_SIGNALING-0.230
  • ESTROGEN_RESPONSE_EARLY-0.220
  • INTERFERON_GAMMA_RESPONSE-0.210
  • KRAS_SIGNALING_DN-0.180
  • MYOGENESIS-0.160
  • DNA_REPAIR-0.120

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR4195651
colon-landscapes@1
——0.780
2ERR2278858
head-neck@1
——0.769
3TCGA-D8-A1JJ-01A-31R-A14M-07
breast-umap@18
—C0.769
4MBCProject_5953_T1_RNA
breast-umap@18
—B0.762
5TCGA-OR-A5L4-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.746
6TCGA-E2-A1B0-01A-11R-A12P-07
breast-umap@18
—C0.739
7SRR4195661
colon-landscapes@1
——0.735
8MNG56
mng-umap@100
——0.734
9SRR6013570
lung-landscapes@6
—cohortSQ10.730
10SRR10900569
melanoma-umap@29
——0.727

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.480Inavolisib— uncovered
PROTEIN_SECRETION0.470Remibrutinib— uncovered
MTORC1_SIGNALING0.370Inavolisib— uncovered
E2F_TARGETS0.350Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.330Inavolisib— uncovered
ANDROGEN_RESPONSE0.320Inavolisib— uncovered
ANGIOGENESIS0.310Remibrutinib— uncovered
G2M_CHECKPOINT0.310Inavolisib— uncovered
COAGULATION0.290Binimetinib— uncovered
HYPOXIA0.280Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.280Idelalisib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
SPERMATOGENESIS0.220Inavolisib— uncovered
UV_RESPONSE_DN0.220Inavolisib— uncovered
COMPLEMENT0.210Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.180Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.170Remibrutinib— uncovered
GLYCOLYSIS0.150Inavolisib— uncovered
HEDGEHOG_SIGNALING0.150Inavolisib— uncovered
TGF_BETA_SIGNALING0.150Inavolisib— uncovered